Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findingsPatients in the TED studies demonstrated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results